Fibrinogen concentrate as first-line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100×109/L

Blood Transfusion

Volumn 13, Issue 2, 2015, Pages 248-254

  Solomon, Cristina ^a,b   Rahe Meyer, Niels ^c,d  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b CSL BEHRING GMBH   (Germany)

^c FRANZISKUS HOSPITAL   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Blood component transfusion; Cardiopulmonary bypass; Fibrinogen; Haemostasis

Indexed keywords

FIBRINOGEN CONCENTRATE; FIBRINOGEN;

ADULT; AORTA SURGERY; ARTICLE; BLOOD COMPONENT; BLOOD COMPONENT THERAPY; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RANK SUM TEST; THROMBOCYTE COUNT; AGED; AORTA; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURGERY; THROMBOCYTE TRANSFUSION;

AGED; AORTA; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET TRANSFUSION; PROSPECTIVE STUDIES;

EID: 84927510922     PISSN: 17232007     EISSN: 23852070     Source Type: Journal    
DOI: 10.2450/2014.0147-14     Document Type: Article

References (24)

1. Diaz-Martin A, Escoresca-Ortega AM, Hernandez-Caballero C, et al. Considerations regarding major bleeding after cardiac transplantation. Transplant Proc 2010;42:3204-5.
2. Bjursten H, Al-Rashidi F, Dardashti A, et al. Risks associated with the transfusion of various blood products in aortic valve replacement. Ann Thorac Surg 2013;96:494-9.
3. Virchow R. Faserstoffarten und fibrinogene Substanz. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 1847;1:581.
4. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995;81:360-5.
5. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005;93:1101-7.
6. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010;104:555-62.
7. Solomon C, Rahe-Meyer N, Sorensen B. Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery. Thromb Res 2011;128:277-82.
8. Karlsson M, Ternstrom L, Hyllner M, et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008;48:2152-8.
9. Reinhofer M, Brauer M, Franke U, et al. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis 2008;19:212-9.
10. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382.
11. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009;102:785-92.
12. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013;118:40-50.
13. Rahe-Meyer N, Hanke A, Schmidt DS, et al. Fibrinogen concentrate reduces intraoperative bleeding when used as firstline hemostatic therapy during major aortic replacement surgery: Results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg 2013;145(3 Suppl):S178-85.
14. Solomon C, Hagl C, Rahe-Meyer N. Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 2013;110:947-56.
15. Lang T, Johanning K, Metzler H, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009;108:751-8.
16. Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-ofcare coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011;115:1179-91.
17. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2014;54:109-18.
18. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008;101:769-73.
19. Hartmann M, Sucker C, Boehm O, et al. Effects of cardiac surgery on hemostasis. Transfus Med Rev 2006;20:230-41.
20. Oshita K, Az-ma T, Osawa Y, Yuge O. Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 1999;89:296-9.
21. Velik-Salchner C, Haas T, Innerhofer P, et al. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007;5:1019-25.
22. Tanaka KA, Taketomi T, Szlam F, et al. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008;106:732-8.
23. Solomon C, Schochl H, Hanke A, et al. Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. Scand J Clin Lab Invest 2012;72:121-8.
24. Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal